Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
批准号:
8383276
负责人:
Xifeng Wu
金额:
$54.6万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-01 至 2016-06-30
关键词:
AddressAgeAnabolismBinding ProteinsBiologicalBiologyCancer CenterCase-Control StudiesCellsCollectionCpG IslandsDNADNA MethylationDNA copy numberDataDatabasesDevelopmentDietDietary intakeDigit structureEnergy-Generating ResourcesEnzymesEpidemiologyEpigenetic ProcessEthnic OriginEtiologyEventFrequenciesFundingGenderGene FrequencyGene MutationGenerationsGenesGeneticGenetic PolymorphismGenetic VariationGenotypeGrantHaplotypesHeritabilityHomeostasisIncidenceIndividualJointsLightLinkMalignant NeoplasmsMeasuresMethylationMicroRNAsMinorMitochondriaMitochondrial DNAMolecularMolecular ProfilingNIH Program AnnouncementsNewly DiagnosedNormal tissue morphologyObesityPathogenesisPathway interactionsPatientsPatternPhenotypePhysical activityPilot ProjectsPloidiesPredispositionRecruitment ActivityRenal Cell CarcinomaReportingResearchResearch DesignResearch Project GrantsRiskRisk FactorsRoleSiteStagingTestingTexasTimeTumor TissueVariantbasecancer riskdesignenergy balancegenome wide association studyinnovationinsightnovelresidenceresponsetumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application is submitted in response RFA-CA-11-011 "Research Answers to NCI's Provocative Questions (R01)" and specifically focuses on addressing PQ-1: "How does obesity contribute to cancer risk?" This application builds upon the large collection of biospecimens including germline DNA, normal and tumor tissues, and comprehensive epidemiology data including diet, obesity, and physical activity of an ongoing renal cell carcinoma (RCC) case control study from Texas. Currently, we have accrued 1,270 patients with newly diagnosed RCC of Texas residence from MD Anderson Cancer Center and 1,200 matched controls identified from random digit dialing of Texas residents. By the time the grant is funded, we estimate to recruit at least 50 cases and 50 controls. We plan to recruit an additional 350 patients and 350 controls. The application will investigate the role of obesity and energy balance in modulating RCC risk as a step towards a clear understanding of the factors that contribute jointly to obesity and cancer development. We will test the hypothesis that obesity-related genetic variations, mtDNA alterations, and epigenetic status (microRNA and methylation) drive RCC tumorigenesis, and interactions among these factors with obesity and energy balance (dietary intake and physical activity) can further modulate risk. Towards this, we will explore 4 specific aims: 1) To identify novel germline susceptibility loci for RCC risk focusig on obesity-related loci and variation in methylation and miRNA pathways. We will use two-stage design to first screen ~ 10,000 previously identified obesity-related loci and potential functional
and haplotype-tagging SNPs in epigenetic pathway genes in 800 cases and 800 controls and then validate top 500 SNPs in additional 800 cases and 800 controls; 2) To determine the effect of mtDNA alterations (copy number and genetic variations) on RCC risk and evaluate the joint effect of mtDNA alterations, obesity, diet, physical activity, and genetic variation identified in im 1 in modulating RCC risk. We will measure mtDNA copy number and genotype all the 144 mitochondrial SNPs with a minor allele frequency >1% in 1,600 cases and 1,600 controls; 3) To identify CpG island methylation of obesity-related genes and miRNA expression patterns in 400 paired RCC tumors and adjacent normal tissues and global methylation status in 1,600 cases and 1,600 controls and 400 paired RCC tumors and adjacent normal tissues; We will determine the interplay between of obesity and energy balance on these phenotypes; 4) To assess genotype-phenotype correlations in obesity-related pathways and mtDNA content and epigenetic events. By integrating epidemiological data, germline genetic variations associated with obesity and epigenetic alterations, mitochondrial function, and profiling of epigenetic alterations in tumors, this comprehensive project will not only shed significant light into the etiology and pathogenesis of RCC, but also identify the commonality of these molecular pathways in obesity and cancer development.
PUBLIC HEALTH RELEVANCE: The incidence of renal cell carcinoma (RCC) has been steadily increasing in the past 2 decades at 2% per year and obesity is a major risk factor for RCC. There has been accumulating evidence that obesity and energy imbalance (e.g., dietary intake, and physical activity) leads increased cancer risk; therefore, we designed this study to systemically evaluate the interplay of obesity and obesity-related genetic variation and phenotypes, such as mtDNA alterations and epigenetic patterns (methylation and microRNA expression), in the etiology and pathogenesis of RCC. The results will provide insight regarding the key pathways that link obesity to cancer development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome
-
批准号:8731333
-
项目类别:
-
资助金额:$10.57万
-
财政年份:2013
-
负责人:Xifeng Wu
-
依托单位:
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
-
批准号:8538909
-
项目类别:
-
资助金额:$50.53万
-
财政年份:2012
-
负责人:Xifeng Wu
-
依托单位:
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
-
批准号:8686604
-
项目类别:
-
资助金额:$52.12万
-
财政年份:2012
-
负责人:Xifeng Wu
-
依托单位:
4th Meeting of the International Consortium of Bladder Cancer (ICBC)
-
批准号:8006232
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2010
-
负责人:Xifeng Wu
-
依托单位:
Lung Cancer Chemoradiation: Predictors of Survival
-
批准号:7939475
-
项目类别:
-
资助金额:$24.32万
-
财政年份:2009
-
负责人:Xifeng Wu
-
依托单位:
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome
-
批准号:7921399
-
项目类别:
-
资助金额:$35.47万
-
财政年份:2009
-
负责人:Xifeng Wu
-
依托单位:
Genome-Wide Association Analysis of Bladder Cancer
-
批准号:7935041
-
项目类别:
-
资助金额:$30.58万
-
财政年份:2009
-
负责人:Xifeng Wu
-
依托单位:
Genome-Wide Association Analysis of Bladder Cancer
-
批准号:8054297
-
项目类别:
-
资助金额:$66.95万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Markers of Susceptibility as Predictors of Blasser Cancer Recurrence
-
批准号:7729505
-
项目类别:
-
资助金额:$19.2万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genome-Wide Association Analysis of Bladder Cancer
-
批准号:7591153
-
项目类别:
-
资助金额:$109.06万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genetic Instability & Risk for Esophageal Carcinoma
-
批准号:7584203
-
项目类别:
-
资助金额:$58.86万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genetic Instability & Risk for Esophageal Carcinoma
-
批准号:7766952
-
项目类别:
-
资助金额:$59.89万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genome-Wide Association Analysis of Bladder Cancer
-
批准号:7799290
-
项目类别:
-
资助金额:$119.64万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome
-
批准号:7507382
-
项目类别:
-
资助金额:$28.33万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
P2: Cancer Risk Assessment in Patients with Oral Premalignant Lesions
-
批准号:7510672
-
项目类别:
-
资助金额:$22.03万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genetic Instability & Risk for Esophageal Carcinoma
-
批准号:8015279
-
项目类别:
-
资助金额:$57.95万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genome-Wide Association Analysis of Bladder Cancer
-
批准号:7387530
-
项目类别:
-
资助金额:$107.74万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genome-Wide Association Analysis of Bladder Cancer
-
批准号:8242887
-
项目类别:
-
资助金额:$76.91万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genetic Instability & Risk for Esophageal Carcinoma
-
批准号:7472226
-
项目类别:
-
资助金额:$58.97万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
Genetic Instability & Risk for Esophageal Carcinoma
-
批准号:8212588
-
项目类别:
-
资助金额:$50.39万
-
财政年份:2008
-
负责人:Xifeng Wu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: